The role of intermittent levosimendan infusions in patients with advanced heart failure: is it enough?

12 May 2024 (09:00 - 10:36)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Ines Gomes Campos

Hospital Centre do Tamega e Sousa, Penafiel (Portugal)

4 More presentations in this session

Presentation thumbnail

Predictors of complete evidence-based treatment implementation at hospital discharge of acute heart failure with reduced LVEF in a real-world population

Doctor S. Ruiz Bustillo (Barcelona, ES)

Abstract Slides Video

Presentation thumbnail

12-Month effect of Tafamidis on the clinical progression of cardiac amyloidosis in a single centre cohort

Doctor R. Carvalheiro (Lisbon, PT)

Abstract Slides Video

Presentation thumbnail

Optimizing heart failure management: impact of quadruple therapy initiation at discharge following decompensation events in patients with reduced ejection fraction

Doctor C. Gregorio (Lisbon, PT)

Abstract Slides Video

Presentation thumbnail

Tolerance and clinical response to SGL2 inhibitors in Fabry disease

Doctor I. Mattig (Berlin, DE)

Abstract Slides Video

Access the full session

Session thumbnail

ePosters in chronic heart failure - pharmacotherapy 3

The Event

Event poster

Heart Failure 2024

12 May 2024 09:00 CET

You may be interested in

Congress Presentation

The experience of more than three hundred levosimendan administrations: what we have learned

Congress Presentation

Intermittent levosimendan in advanced palliative heart failure improves quality of life and reduces heart failure decompensations: a single center-experience

Congress Presentation

Levosimendan in advanced heart failure: a step forward in functional recovery and hospitalization reduction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources